WhiteLab Genomics closed a €23.2 million Series B led by AVP to accelerate AI-driven genomic medicine development.
- Amount
- $26.1M
- Stage
- Series B
- Announced
- 6 October 2026
- Lead
- AVP
- Other investors
- Yaday Health, Blast Club, Omnes Capital, Debiopharm Innovation Fund
- Use of funds
- Accelerates in vivo validation programs and commercial expansion across North America, Europe and Asia.
- Total raised
- $37M to date
- Checked
- Amount and date matched across 2 press sources